AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationHematopoietic Stem Cell MobilizationTransplantation ConditioningTransplantation, HomologousGranulocyte Colony-Stimulating FactorMelphalanCombined Modality TherapyLeukapheresisAntigens, CD34Hematologic NeoplasmsStem Cell TransplantationBlood Component RemovalMultiple MyelomaCyclophosphamideBone Marrow TransplantationAntineoplastic Combined Chemotherapy ProtocolsGraft vs Host DiseaseBusulfanMyeloablative AgonistsTreatment OutcomeGraft SurvivalLymphoma, Non-HodgkinHematopoietic Stem CellsEtoposideRemission InductionAntineoplastic Agents, AlkylatingRecurrenceThiotepaCarmustineSalvage TherapyCytophagocytosisVincristineIfosfamideCytarabineHodgkin DiseaseHematopoiesisDisease-Free SurvivalStem CellsAmyloidosisCord Blood Stem Cell TransplantationTransplantation ChimeraRetrospective StudiesTissue DonorsGranulocytesSurvival RateWhole-Body IrradiationSurvival AnalysisNeoplasmsTime FactorsLiver TransplantationDoxorubicinInfectionImmunosuppressive AgentsHistocompatibilityLymphoma, T-CellBone Marrow PurgingPrednisonePlatelet CountHistocompatibility TestingTransplantation, IsogeneicLeukemia, Myeloid, AcutePOEMS SyndromeDexamethasoneFollow-Up StudiesCarboplatinBlood Cell CountLeukemiaRecombinant ProteinsVidarabineLymphomaAntineoplastic AgentsFeasibility StudiesProspective StudiesKidney TransplantationCytomegalovirus InfectionsBlood Transfusion, AutologousBlood CellsGraft vs Leukemia EffectFatal OutcomeMyelodysplastic SyndromesCell TransplantationBone MarrowAnemia, AplasticImmunophenotypingPrognosisT-LymphocytesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCell SeparationLymphocyte DepletionImmunosuppressionCyclosporineHLA AntigensLeukocytes, MononuclearHematologic DiseasesTransplantation ImmunologyMesenchymal Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaOpportunistic Infections
Progenitor cellMobilizationHSCTMyeloidLymphocytesReceiving granulocyte colonyEngraftmentMesenchymalHigh-doseMultiple myelomaPatient'sClinicalCyclophosphamideFollowed by hematopoieticCD34DonorRecombinantLymphoidHematopoietic cell transplantationMarrow transplantationImmuneTransplantEfficacyProliferationApheresisPediatricTherapyPlateletPlateletsMethodsEtoposideProspective randomizedUnderwentTumor cellsColonySevereSolid tumorsSurvivalDifferentiationSignificantlyHematologicInfusionImmatureGraftFeasibilityRelapsePluripotentDiseaseSignificant
Progenitor cell12
  • Flow cytometric applications for CD34+ cell identification and enumeration provide a rapid, quantitative and reproducible method to evaluate the progenitor cell population. (bdbiosciences.com)
  • Progenitor cell therapy describes the use of multipotent cells of various cell lineages (autologous or allogeneic) for tissue repair and/or regeneration. (southcarolinablues.com)
  • Progenitor cell therapy is being investigated for the treatment of damaged myocardium resulting from acute or chronic cardiac ischemia and for refractory angina. (southcarolinablues.com)
  • For individuals who have acute cardiac ischemia who receive progenitor cell therapy, the evidence includes 2 randomized controlled trials (RCTs) with 200 patients, numerous small RCTs, and meta-analyses of these RCTs. (southcarolinablues.com)
  • Overall, this evidence has suggested that progenitor cell treatment may be a promising intervention, but robust data on clinical outcomes are lacking. (southcarolinablues.com)
  • For individuals who have chronic cardiac ischemia who receive progenitor cell therapy, the evidence includes a nonrandomized comparative trial and systematic reviews of smaller RCTs. (southcarolinablues.com)
  • Results of the nonrandomized trial are encouraging, because this is the first controlled trial that has reported a significant mortality benefit for progenitor cell treatment. (southcarolinablues.com)
  • For individuals who have refractory angina who receive progenitor cell therapy, the evidence includes phase 2 trials and a phase 3 pivotal trial. (southcarolinablues.com)
  • Additional larger trials are needed to determine whether progenitor cell therapy improves health outcomes in patients with refractory angina. (southcarolinablues.com)
  • No obvious correlations between clinical parameters, including age, karyotype, existence of paroxysmal nocturnal hemoglobinuria clones, pretreatment blood counts, progenitor cell counts, and the response to immunosuppressive therapy (IST), were found. (springermedizin.at)
  • Enhancement of human erythroid progenitor cell growth by media conditioned by a human t-lymphocyte line. (shengsci.com)
  • Progenitor cell (stem cell) lines in the bone marrow produce new blood cells and stromal cells. (medscape.com)
Mobilization13
  • Plerixafor may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. (fresenius-kabi.com)
  • Therefore, Plerixafor is not intended for HSC mobilization and harvest in patients with leukemia. (fresenius-kabi.com)
  • In patients treated with Plerixafor in combination with G-CSF for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. (fresenius-kabi.com)
  • Peripheral blood stem cells were obtained by leukapheresis after mobilization with granulocyte colony-stimulating factor. (cellsurgicalnetwork.com)
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. (uchicago.edu)
  • This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)
  • Quantitating the CD34+ cell population can also be useful during mobilization as well as for determining the optimal timing of apheresis sessions to make sure that enough CD34+ cells have been harvested. (bdbiosciences.com)
  • We evaluated hematopoietic stem cells according to CD34 expression and aldehyde dehydrogenase (ALDH) activity in peripheral blood and apheresis product samples from patients after mobilization with granulocyte-colony-stimulating factor (G-CSF) alone or G-CSF after high-dose cyclophosphamide (4 g/m(2) once daily, intravenously on day 1). (ogu.edu.tr)
  • According to our data, numbers of SSClo ALDH(br) cells are in very good agreement with numbers of SSClo CD45(dim) CD34(hi) cells and can be a predictor of stem cell mobilization. (ogu.edu.tr)
  • use of mobilization drugs to decrease HSPC retention in the bone marrow and allow their mobilization to the peripheral blood). (fredhutch.org)
HSCT13
Myeloid18
  • Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. (uchicago.edu)
  • Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. (uchicago.edu)
  • Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. (uchicago.edu)
  • Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. (uchicago.edu)
  • PD-1 is expressed on activated T cells, B cells, and myeloid cells. (biomedcentral.com)
  • Therapy-related myeloid neoplasms (t-MNs) are defined by the World Health Organization (WHO) as a distinct heterogeneous group of clonal hematopoietic stem cell disorders that are directly related to previous cytotoxic chemotherapy and/or radiation therapy. (medscape.com)
  • Acute myeloid leukemia from a patient who presented 10 months after therapy with topoisomerase II inhibitor. (medscape.com)
  • Approximately 30% of therapy-related myeloid neoplasm (t-MN) cases involve patients treated for nonneoplastic disorders, and those treated with high-dose chemotherapy followed by autologous stem cell transplantation. (medscape.com)
  • There was 93% donor T-lymphocytes, 20% donor B-lymphocytes, and 5% donor myeloid cells, indicative of some donor stem cell engraftment. (frontiersin.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. (ashpublications.org)
  • Therapy-related myeloid neoplasms (t-MN) are defined by the World Health Organization (WHO) as clonal hematopoietic stem cell disorders related to previous exposure to chemotherapy and/or radiation therapy. (medscape.com)
  • Approximately 30% of therapy-related myeloid neoplasms (t-MN) cases involve patients treated for non-neoplastic disorders, and those treated with high-dose chemotherapy followed by autologous stem cell transplantation. (medscape.com)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • Several patients with clinical features of chronic myeloid leukemia (CML) have fusion of the TEL (ETV6) gene on 12p13 with ABL on 9q34 and express a chimeric Tel-Abl protein that contains the same portion of the Abl tyrosine kinase fused to Tel, an Ets family transcription factor, rather than Bcr. (shengsci.com)
  • The common stem cell produces 2 other stem cells, the myeloid stem cell and the lymphoid stem cell. (medscape.com)
Lymphocytes8
  • Peripheral blood lymphocytes were analysed by flow cytometry, ELISA, and T-cell-receptor spectratyping before and after transplantation. (northwestern.edu)
  • 3 Autologous stem cell transplantation almost exclusively uses peripheral blood, while for allogeneic SCT, T-lymphocytes in the peripheral blood could pose some danger. (bdbiosciences.com)
  • To limit loss of CD34 + cells, the procedure was modified to remove T and B lymphocytes, monocytes and granulocytes from bone marrow or mobilized peripheral blood leukapharesis cell products (ie. (fredhutch.org)
  • These results suggest that the exposure to environmental pollutants in utero affects genetic constitution of fetus and increases MN values in their body cells, which is detectable right after birth in peripheral blood lymphocytes. (go.jp)
  • Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. (uchc.edu)
  • Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. (uchc.edu)
  • Recent studies have shown that soluble factors elaborated by human T lymphocytes enhance erythroid burst formation by human peripheral blood null cells. (shengsci.com)
  • T lymphocytes originate via lymphoid stem cells that migrate to the thymus and differentiate under the influence of the thymic hormones thymopoietin and thymosin. (medscape.com)
Receiving granulocyte colony1
Engraftment11
  • We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. (nature.com)
  • Cell therapy is a potential new treatment for post MI patients, but the main challenges are : the necessity to preserve immune competency and to gain adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • Repair of scar tissue constitutes a challenge for cardiac stem cell therapy due to lack of adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • We also investigated the relationship between the number of SSClo CD45(dim) CD34(hi) cells, SSClo ALDH(br) cells and engraftment. (ogu.edu.tr)
  • Incomplete engraftment (poor graft function) requires the patient to undergo more transfusions of red cells or platelets. (drugdiscoverynews.com)
  • One trial is testing whether MSCs with or without peripheral blood stem cells could treat poor graft function and delayed platelet engraftment. (drugdiscoverynews.com)
  • However, HLA-identical sibling stem cell infusions in ADA-SCID result in some donor stem cell engraftment and long-term thymopoiesis. (frontiersin.org)
  • As explained by Dr. Adair, "our previous work and in research done by others in the field, there has been a clear need to correct the FA defect to elicit engraftment of FA cells. (fredhutch.org)
  • When asked about future directions, Dr. Adair concluded: "Of course we are interested to see whether the enhanced engraftment observed in mice plays out in our patients. (fredhutch.org)
  • We hope that this study will demonstrate the ability to not only isolate more of this limited stem cell pool from FA patients, but will also render these fewer cells more fit for engraftment. (fredhutch.org)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
Mesenchymal6
  • The bone morrow contains several stem cell types including hematopoetic stem cells, endothelial progenitor cells, mesenchymal (stromal) stem cells and multipotent adult progenitor cells. (escardio.org)
  • Granulocyte-colony stimulating factor (G-CSF)-mobilized, T cell-depleted haploidentical paternal stem cells were infused on day 0 together with cultured donor mesenchymal stem cells. (lu.se)
  • PLX-R18 cells, derived from mesenchymal-like cells collected from donated placentas, are designed to release a combination of therapeutic proteins to jumpstart the regeneration of a poorly functioning hematopoietic system. (drugdiscoverynews.com)
  • While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. (biomedcentral.com)
  • There are many studies involving autologous therapies and some allogenic therapies, based on the recovery of mobilized bone marrow cells, including mesenchymal stem cells (MSCs) and adipose derived stem cells that also include the stromal or adherent cell type that has an MSC phenotype. (biomedcentral.com)
  • The bone marrow stroma contains mesenchymal stem cells. (medscape.com)
High-dose11
Multiple myeloma9
Patient's7
  • Cells from the patient's sister's bone marrow were administered, and in the following weeks successfully began dividing and differentiating into white blood cells. (wikipedia.org)
  • However, several weeks later, the cells were found to have been mutated by the radiation still present within the patient's body, and were observed carrying out autoimmune responses. (wikipedia.org)
  • CONCLUSION:These results indicate that the introduction of cabazitaxel for Japanese mCRPC patients could result in oncological outcomes without any association with patient's age and the profiles of previous docetaxel therapy. (shengsci.com)
  • The use of patient's own bone marrow aspirates, hematopoietic stem cells and MSCs, for heart muscle tissue repair can be puzzling because these cells do not normally contribute to the cardiac lineage types that are desired. (biomedcentral.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • The stem cells are isolated from the patient's own blood and cultured. (tci-thaijo.org)
  • 1. Definition: GVHD develops when the donor's immune cells mistakenly attack the patient's normal cells. (drcremers.com)
Clinical24
  • Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. (cellsurgicalnetwork.com)
  • To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. (cellsurgicalnetwork.com)
  • Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
  • abstract： PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
  • Pancreatic islet transplantation (ITx) has moved from the experimental phase of development to a position of an accepted and appropriate procedure to apply in clinical medicine. (lidsen.com)
  • Preclinical and some small-scaled clinical trials have suggested feasibility and safety of cardiac stem cell therapy. (escardio.org)
  • However, there are still questions waiting for answers and results of large-scale randomized trials are needed for the appearance of myocardial cellular therapy as a clinical therapeutic option for patients with ischemic heart disease. (escardio.org)
  • Cell therapy is currently emerging as a potential new treatment for post MI patients with the assumption that recolonization of the areas of scarred myocardium with exogenously supplied surrogates or precursors of cardiomyocytes can restore function and ultimately affect clinical outcomes. (escardio.org)
  • Various cell types have been tested experimentally for cardiac repair so far, but only those of autologous origin have yet undergone clinical testing due to immune competency. (escardio.org)
  • In experimental and clinical studies unselected mononuclear bone marrow cells as well as specific subpopulations have been used for transplantation. (escardio.org)
  • Limited evidence on clinical outcomes has suggested that there may be benefits from improving left ventricular ejection fraction, reducing recurrent myocardial infarction, decreasing need for further revascularization, and perhaps even decreasing mortality, although a recent, large, individual patient data meta-analysis reported no improvement in these outcomes. (southcarolinablues.com)
  • In recent years, clinical trials with stem cells have taken the emerging field in many new directions. (biomedcentral.com)
  • The rapid advance of stem cell clinical trials for a broad spectrum of conditions warrants an update of the review by Trounson (2009) [ 1 ]. (biomedcentral.com)
  • There has been a rapid surge in clinical trials involving stem cell therapies over the last two to three years and those trials are establishing the clinical pathways for an emergent new medicine. (biomedcentral.com)
  • Placenta-derived stem cells are being considered for similar uses and are in Phase III clinical trial for critical limb ischemia by Israel's Pluristem Therapeutics. (biomedcentral.com)
  • A significant proportion of clinical studies that are underway involve bone marrow and cord blood stem cells for blood and immune disorders [ 3 ] and cancers. (biomedcentral.com)
  • Several of those are now considered applicable for patient treatments beyond the need for regulated clinical trials. (biomedcentral.com)
  • We have chosen to concentrate on the emerging therapeutics that broadly involves a wide range of cell types in clinical trials registered on the National Institutes of Health's clinical trials web site. (biomedcentral.com)
  • The public clinical trials database http://clinicaltrials.gov shows 123 clinical trials using MSCs for a very wide range of therapeutic applications (Figure 1 ), the majority of which are in Phase I (safety studies), Phase II (proof of concept for efficacy in human patients), or a mixture of PhaseI/II studies (Figure 2 ). (biomedcentral.com)
  • We analyzed the clinical course and outcome in 50 patients (27 males, 23 females) suffering from aplastic anemia (AA), treated in our department between 1987 and 2007. (springermedizin.at)
  • Includes advanced clinical parameters, including NRBCs with every CBC, Immature Granulocytes with every Diff, RET-He within the Reticulocyte profile and a fluorescent platelet channel for Immature Platelet Fraction (IPF). (kiranhospital.com)
  • Drs. Jennifer Adair and Hans-Peter Kiem, in collaboration with Drs. Ann Woolfrey, Pamela Becker and Lauri Burroughs (Clinical Research Division) have been investigating the feasibility of gene therapy for FA patients in clinical trial. (fredhutch.org)
  • First case clinical study records described the development of severe or mild respiratory distress in patients with severe pancreatitis, sepsis, nonthoracic injuries, massive transfusion, and other conditions. (ceufast.com)
  • In clinical studies of patients with high-risk neuroblastoma, Grade 3 peripheral sensory neuropathy occurred in 2% to 9% of patients. (nih.gov)
Cyclophosphamide3
Followed by hematopoietic1
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
CD3417
  • Patients underwent dose-intense immune suppression and autologous haemopoietic stem-cell (CD34) infusion. (northwestern.edu)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • 4 CD34 expression is historically related to hematopoietic cells and it is considered as the marker of HSCs. (bdbiosciences.com)
  • An accurate measurement of CD34 is critical for dose requirement protocols in stem cell transplantation. (bdbiosciences.com)
  • 6 Fluorochrome-conjugated monoclonal antibodies directed against CD34 molecule can be used to identify CD34+ cells by flow cytometry. (bdbiosciences.com)
  • Numbers of SSClo CD45(dim) CD34(hi) cells and SSClo ALDH(br) cells were highly correlated in both peripheral blood and apheresis products (P (ogu.edu.tr)
  • We could not find a relationship between the transplanted SSClo CD45(dim) CD34(hi) cell dose or SSClo ALDH(br) cell dose and platelet or neutrophil recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo CD45(dim) CD34(hi) cells were 5.40 x 106/kg for neutrophil recovery and 7.22 x 106/kg for platelet recovery. (ogu.edu.tr)
  • HSPCs are characterized by expression of the CD34 marker, which is used for cell enrichment followed by overnight transduction with a viral vector carrying the wild type FANCA gene, commonly mutated in FA. (fredhutch.org)
  • However, the low frequency of CD34 + cells in FA patients limits the numbers of HSPCs that can be obtained by direct enrichment of CD34 + cells from the bone marrow. (fredhutch.org)
  • This method of lineage depletion rather than cell enrichment limits CD34 + cell loss and manipulation. (fredhutch.org)
  • When tested on healthy donor bone marrow cells, the lineage depleted cells and CD34 + -enriched cells were transduced with similar efficiencies by the FANCA-carrying viral vector. (fredhutch.org)
  • This could be due to the lineage depletion process being more gentle on the CD34 + cells since it is an indirect enrichment rather than a direct enrichment. (fredhutch.org)
  • It could also be due to supporting cells in the graft, which are normally excluded when CD34 + cells are directly enriched. (fredhutch.org)
  • The purity of the CD34 + cells was higher than for the first two patients who underwent direct CD34 enrichment, and the transduction efficiency was similar. (fredhutch.org)
  • The international FA Gene Therapy Working Group recommends direct CD34+ cells enrichment using beads binding to the CD34 marker. (fredhutch.org)
  • One of the reasons for this is the lack of repopulating cells obtained in prior methods of isolation, such as CD34 enrichment, and the other major reason for this is the systemic toxicity of conditioning regimens which include DNA-damaging chemotherapy. (fredhutch.org)
Donor12
  • Immature hematopoietic stem cells in the circulating blood that are similar to those in the bone marrow are collected by apheresis from a donor (PBSC collection). (wikipedia.org)
  • The apheresis procedure typically lasts for 4-6 hours, depending on the blood volume of the donor. (wikipedia.org)
  • For example, calculations must be made to ensure consistency in the amount of total blood volume between the donor and recipient. (wikipedia.org)
  • If the total blood volume of the donor is less than that of the recipient (such as when a child is donating to an adult), multiple PBSCT sessions may be required for adequate collection. (wikipedia.org)
  • of these, 53 percent are autologous (taken from the patient) and 47 percent are allogenic (taken from a donor other than the patient). (drugdiscoverynews.com)
  • She received a matched sibling donor unconditioned stem cell infusion at 16 months of age. (frontiersin.org)
  • Because only one fourth of patients have such a sibling donor, mismatched related or matched unrelated donors (identified through international registries) are often used. (msdmanuals.com)
  • Seven patients were transplanted using a matched sibling donor upfront, and one patient was treated with CSA and growth factors only. (springermedizin.at)
  • Single donor platelet(SDP) apheresis is collected from healthy donors using the apheresis machines.These platelets can effectively increase platelet counts and are maximally utilized by patients with Low platelets in Dingue, hemat-oncological disorders.Single donor platelets reduce the number of donor exposures compared to random donor platelets prepared from blood donations. (kiranhospital.com)
  • Five patients had progressive disease, two patients had stable disease, and one patient experienced a partial response after receiving donor lymphocyte infusions and IFN-α. (aacrjournals.org)
  • Its severity depends on the differences in tissue type between patient and donor. (drcremers.com)
  • The drying and scarring effects of the attack by the donor cells can affect the inside of the mouth and the esophagus (from the throat to the stomach), causing them to become excessively dry and damaged. (drcremers.com)
Recombinant1
Lymphoid2
  • Acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. (medscape.com)
  • The malignant cells of ALL are lymphoid precursor cells (ie, lymphoblasts) that are arrested in an early stage of development. (medscape.com)
Hematopoietic cell transplantation2
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
Marrow transplantation5
Immune8
  • We investigated the safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients. (northwestern.edu)
  • The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
  • Such immune dysfunction may be due to a disorder in thymic output function (in particular in young patients), which results in a lower level of naive T-cells in the peripheral blood available for an immune response to the proliferation and abnormal expression of the T cell receptor (TCR) repertoire. (biomedcentral.com)
  • Moreover, increasing data have shown that peripheral T-cell tolerance is an essential property of the specific immune response to tumor cells. (biomedcentral.com)
  • This includes bone and cartilage repair, cell types into which MSCs readily differentiate, and immune conditions such as graft versus host disease and autoimmune conditions that utilize the MSC's immune suppressive properties. (biomedcentral.com)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • As a consequence, blood cell counts are very low in patients and the immune system is severely weakened. (fredhutch.org)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
Transplant10
  • An early example of a successful peripheral stem cell transplant was carried out in the wake of the 1999 Tokaimura nuclear accident. (wikipedia.org)
  • A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. (biomedcentral.com)
  • Transplant Cell Ther. (uchicago.edu)
  • Biol Blood Marrow Transplant. (uchicago.edu)
  • A tandem autologous transplant, also known as a double autologous transplant, requires the patient to undergo two planned autologous stem cell transplants within 6 months. (cancertreatmenttoday.org)
  • Stem cells are collected once before the initial transplant and half are used for each procedure. (cancertreatmenttoday.org)
  • On the other hand, for patients who have not responded completely, NCCN recommends second transplant. (cancertreatmenttoday.org)
  • In addition, it has yet to be determined which patients benefit most from a tandem transplant. (cancertreatmenttoday.org)
  • The issue of allogeneic after autologous transplant is reviewed under a separate heading. (cancertreatmenttoday.org)
  • At 4 years of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte and natural killer cell numbers. (frontiersin.org)
Efficacy7
  • MATERIALS AND METHODS:This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic significance of cabazitaxel, focusing on patient age and the correlation of efficacy between docetaxel and cabazitaxel. (shengsci.com)
  • abstract： PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • In the SIMPLIFY-1 multicenter, randomized, double-blind, phase III study, safety and efficacy of momelotinib was compared with ruxolitinib in 432 patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. (medscape.com)
  • To determine the safety and efficacy of intramyocardial autologous blood stem cell injection for cardiomyopathy. (tci-thaijo.org)
  • Ruengsakulrach P, Visudharom K, Chaothawee L, Belkin M. Safety and Efficacy of Intramyocardial Implantation of Peripheral Blood Stem Cell for Cardiomyopathy. (tci-thaijo.org)
  • A dose escalation study was performed to determine in vivo efficacy of IgA3.0 ch14.18 in an intraperitoneal mouse model using 9464D-GD2 neuroblastoma cells as well as in a subcutaneous human xenograft model using IMR32 neuroblastoma cells. (bmj.com)
  • Conclusions IgA3.0 ch14.18 is a promising new therapy for neuroblastoma, showing (1) increased half-life compared to natural IgA antibodies, (2) increased protein stability enabling effortless production and purification, (3) potent CD89-mediated tumor killing in vitro by healthy subjects and patients with neuroblastoma and (4) antitumor efficacy in long-term mouse neuroblastoma models. (bmj.com)
Proliferation6
  • Granulocyte colony stimulating factor (GCSF) are naturally occurring glycoproteins that stimulate white blood cell proliferation. (wikipedia.org)
  • The increase in white blood cell proliferation as a result of the Filgrastim ensures a better results from the donation. (wikipedia.org)
  • It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. (uchicago.edu)
  • Quizartinib and its active metabolite (AC886) inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. (medscape.com)
  • Acute lymphoblastic leukemia (ALL): Bone marrow shows proliferation of large and heterogeneous lymphoblasts consistent with pre-B-cell ALL (French-American-British L2 morphology). (medscape.com)
  • Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. (hemonc.org)
Apheresis1
  • Platelet counts should be monitored in patients who receive Plerixafor and then undergo apheresis. (fresenius-kabi.com)
Pediatric3
  • We provide leukocyte reduction for at risk patients, irradiated components , concentrated platelets for pediatric recipients , autologous collections. (kiranhospital.com)
  • Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. (nih.gov)
  • Moreover, oral mucositis induces pediatric patients to reduce food intake, which affects their nutritional status and makes them less responsive to treatment 4-5 . (bvsalud.org)
Therapy24
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • Univariate and multivariate analyses revealed that there were no significant correlation of patient age (p = 0.537), the response to prior docetaxel therapy (p = 0.339) or cycles of docetaxel therapy (p = 0.379) with shorter OS. (shengsci.com)
  • As such, stem cell therapy cannot be regarded as a valid therapeutic option for patients with cardiovascular disease in the present era of evidenced-based medicine, yet it holds great hope for the future. (escardio.org)
  • The ORR was 64% in patients with prior T-cell redirecting therapy. (medscape.com)
  • The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)
  • Five RRNB patients were enrolled: 4 with relapse (3 after autologous SCT) and 1 with induction therapy failure. (lu.se)
  • Patients who are exposed to topoisomerase II inhibitors (eg, etoposide, doxorubicin) tend to present with frank leukemia within 1 year of the time primary therapy was initiated (see the following image). (medscape.com)
  • Two hundred thirty-one patients with symptomatic myeloma were enrolled in Total Therapy I between 1990 and 1995 (Barlogie et al. (cancertreatmenttoday.org)
  • In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice. (cancernetwork.com)
  • Hematopoietic stem cell transplantation is the only potentially curative therapy, but it is only an option for select patients. (cancernetwork.com)
  • Hematology/ Oncology and Stem Cell Therapy. (elsevierpure.com)
  • The only curative therapy is hematopoietic stem cell transplantation. (frontiersin.org)
  • Among all, cell transplantation therapy is considered the most favourable treatment strategy for femoral head necrosis. (ijpsonline.com)
  • The main objective of this communication is to study the treatment of femoral head necrosis with cell replacement therapy and also its effects by focusing on the disease stages. (ijpsonline.com)
  • Human Myoblast Genome Therapy (HMGT) is a platform technology of cell transplantation, nuclear transfer, and tissue engineering. (jgc301.com)
  • Cell therapy, however, holds the promise of repleting the damage heart with new contractile cells that can be engi-neered to secrete concoctions that promote healing by recruiting new blood vessel development or angiogenesis. (jgc301.com)
  • We also examined the numbers of colony-forming progenitor cells (CFUs) before and after therapy. (springermedizin.at)
  • In most responding patients, CFU numbers increased substantially after successful therapy. (springermedizin.at)
  • Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. (springermedizin.at)
  • However, an ongoing limitation in FA gene therapy has been the inability to condition patients prior to gene therapy. (fredhutch.org)
  • This could re-open the door for up-and-coming, non-chemotherapy based conditioning regimens currently under study to improve the therapeutic potential of gene therapy for the many FA patients who do not have suitable allogeneic donors available. (fredhutch.org)
  • In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). (ashpublications.org)
  • Bone Marrow Suppression: Monitor peripheral blood counts during Unituxin therapy. (nih.gov)
  • In spite of widespread use, data supporting specific practice paradigms for whole blood and component therapy transfusion are lacking, the notable exception being in the primary treatment of hemorrhagic shock. (medscape.com)
Platelet4
  • The optimal thresholds for SSClo ALDH(br) cells were 6.53 x 106/kg for neutrophil recovery and 8.72 x 106/kg platelet recovery. (ogu.edu.tr)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • As needed, the stem cells differentiate to become a particular kind of cell-a white blood cell, red blood cell, or platelet. (medscape.com)
  • Fresh whole blood has long been thought of as the criterion standard for transfusion, but the advent of whole blood fractionation techniques subsequent to World War II provided a means of more efficient use of the various components (i.e., packed red blood cells [PRBCs], fresh frozen plasma [FFP], individual factor concentrates, platelet concentrates, cryoprecipitate). (medscape.com)
Platelets4
Methods2
  • METHODS: Prospective, cross-sectional, multicentre, observational study in patients undergoing contrast-enhanced magnetic resonance. (bvsalud.org)
  • Cell Rep Methods. (u-tokyo-hemat.com)
Etoposide1
  • Combination chemotherapy with cisplatin and etoposide (cisplatin-etoposide [PE]) has long been the mainstay of treatment for small cell lung cancer (SCLC). (the-medical-dictionary.com)
Prospective randomized1
  • In this prospective randomized open-label controlled trial, 100 patients 20 to 42 years old with AMH below 2 ng/mL were randomized to priming or control groups (50 patients each). (biomedcentral.com)
Underwent4
  • Thirty-six secondary progressive MS patients, among whom 21 were with OSMS and 15 with CMS, underwent APBSCT and were followed up for an average of 48.92Â months (range, 10-91Â months). (cellsurgicalnetwork.com)
  • Results: Nine patients underwent stem-cell mobilisation but two were excluded before transplantation because of infection. (northwestern.edu)
  • Between May 2005 and February 2010, 126 consecutive patients underwent intramyocardial cell injection. (tci-thaijo.org)
  • All patients initially underwent conventional infertility treatment for 2 consecutive cycles in which the priming group but not controls received a subcutaneous G-CSF priming injection during the early luteal phase. (biomedcentral.com)
Tumor cells4
  • The effect of potential reinfusion of tumor cells has not been well-studied. (fresenius-kabi.com)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • Results ADCC and ADCP assays showed that particularly neutrophils and macrophages from healthy donors, non-human primates and patients with neuroblastoma are able to kill neuroblastoma tumor cells efficiently with IgA3.0 ch14.18. (bmj.com)
Colony9
  • Granulocyte Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (uchicago.edu)
  • This graph shows the total number of publications written about "Granulocyte Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte Colony-Stimulating Factor" was a major or minor topic of these publications. (uchicago.edu)
  • Below are the most recent publications written about "Granulocyte Colony-Stimulating Factor" by people in Profiles. (uchicago.edu)
  • Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. (uchicago.edu)
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
  • The current treatment for incomplete hematopoietic recovery includes administration of factors stimulating white and red blood cell growth, such as granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin. (drugdiscoverynews.com)
  • Granulocyte colony-stimulating factor (G-CSF) administration increased ovarian preantral follicles and anti-Müllerian hormone (AMH) in animal models with diminished ovarian reserve. (biomedcentral.com)
  • The cytokine granulocyte-colony stimulating factor (G-CSF) is known to have trophic and neuroprotective properties in the brain, and we recently identified it as a modulator of neuronal and behavioral plasticity. (jneurosci.org)
  • Here, we report that granulocyte-colony stimulating factor (G-CSF), a pleiotropic cytokine with known trophic and neuroprotective properties in the brain, acts directly on dopaminergic circuits to enhance their function. (jneurosci.org)
Severe9
  • Patients present with recurrent infections associated with T-lymphocytopenia, characteristically presenting later than patients with classical severe combined immunodeficiency (SCID). (frontiersin.org)
  • Patients present with predominantly T-lymphocytopenia, and the immunological presentation characteristically is later than patients with classical severe combined immunodeficiency (SCID) ( 4 ). (frontiersin.org)
  • The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. (tci-thaijo.org)
  • Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. (unicatt.it)
  • Severe peripheral sensory neuropathy ranged from 2% to 9% in patients with neuroblastoma. (nih.gov)
  • Severe peripheral motor neuropathy has also been reported. (nih.gov)
  • Unituxin causes serious neurologic adverse reactions including severe neuropathic pain and peripheral neuropathy. (nih.gov)
  • Severe neuropathic pain occurs in the majority of patients. (nih.gov)
  • A male 13-year-old patient with chondroblastic osteosarcoma in the left distal thigh and acute lymphoblastic leukemia undergoing cancer treatment with methotrexate presented with severe oral mucositis. (bvsalud.org)
Solid tumors1
Survival11
  • The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. (the-medical-dictionary.com)
  • In patients with limited disease (LD), the CR rate is 16 to 18%, with a median survival of 11.7 to 12.4 months. (the-medical-dictionary.com)
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • The final analysis of the landmark French IFM-94 trial demonstrated that double transplantation led to improved survival compared with single transplantation in patients with previously untreated myeloma. (cancertreatmenttoday.org)
  • Preliminary results of several randomized trials comparing tandem and single autologous transplants, which have not been followed as long, have also shown superior event-free survival with the tandem regimen in most studies. (cancertreatmenttoday.org)
  • Additionally, ruxolitinib is the only agent that has demonstrated a survival benefit in patients with MF. (cancernetwork.com)
  • Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. (immunetolerance.org)
  • The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • Opinions are embraced and defended, but transfusion of red blood cells has not reliably demonstrated increased survival, other than in 2 specific populations, as follows: (1) those with active hemorrhage, and (2) those with active cardiac ischemia. (medscape.com)
Differentiation2
  • Moreover, it seems that paracrine action of skeletal myoblasts facilitate neighboring cardiomyocytes to maintain their replicative potential and/or stimulate differentiation of native cardiac stem cells (8,9). (escardio.org)
  • Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. (biomedcentral.com)
Significantly6
  • For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). (cellsurgicalnetwork.com)
  • The regional blood flow in the center and peri-infarct area was significantly increased in animals of groups-3 and -4. (jgc301.com)
  • The sCA-125 levels were significantly higher in noncancer patients than those in the cancer patients, while the pCA-125 levels showed no significant difference between the two groups. (go.jp)
  • Notably, the p/sCA-125 ratio was significantly lower in the noncancer patients than that in the cancer patients. (go.jp)
  • In addition, the urethral caliber, speed of urothelial regeneration, content of smooth muscle, and vessel density were significantly improved in the group with autologous USC-seeded SIS. (biomedcentral.com)
  • With priming, significantly more patients achieved cryopreservation of redundant blastocysts. (biomedcentral.com)
Hematologic1
  • The cells are also being evaluated in a variety of other hematologic indications. (drugdiscoverynews.com)
Infusion4
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • One to two days before your stem cell infusion, you'll take a regimen of drugs to help prevent GVHD. (drcremers.com)
  • Serious and potentially life-threatening infusion reactions occurred in 26% of patients treated with Unituxin. (nih.gov)
  • Monitor patients closely for signs and symptoms of an infusion reaction during and for at least four hours following completion of each Unituxin infusion. (nih.gov)
Immature2
Graft6
  • Analysis of immunologic recovery showed fast reappearance of potentially immunocompetent natural killer (NK) and T cells, which might have acted as effector cells responsible for the graft-versus-tumor (GVT) effect. (lu.se)
  • One patient rejected the graft, was rescued with autologous backup, and died of progressive disease 5 months after transplantation. (lu.se)
  • In another trial, this group is evaluating whether peripheral blood stem cells combined with MSCs can treat poor graft function. (drugdiscoverynews.com)
  • All patients achieved initial mixed hematopoietic chimerism with two patients rejecting their graft and recovering host hematopoiesis. (aacrjournals.org)
  • Four patients developed acute, grade 2 to 3, graft- versus -host disease and four patients developed extensive chronic graft- versus -host disease. (aacrjournals.org)
  • These porous microstructures allow cell infiltration into the matrix and have fewer heterogeneous cellular proteins, thereby preventing complications, such as inflammatory reactions, fibrosis, calcification, and graft shrinkage. (biomedcentral.com)
Feasibility1
  • Here, we demonstrated the feasibility of using autologous urine-derived stem cells (USCs) seeded on small intestinal submucosa (SIS) to repair a urethral defect in a rabbit model. (biomedcentral.com)
Relapse2
  • Among the 22 relapse-free patients, 20 were with continuous neurological improvement without any relapse events, and two remained in neurologically stable states. (cellsurgicalnetwork.com)
  • In addition, PD-1/PD-L1 interactions contribute to functional T-cell impairment, which fails to elicit minimal residual disease and may be related to leukemia relapse. (biomedcentral.com)
Pluripotent2
Disease13
  • Eleven of the 20 OSMS patients (55%) and two of the 15 CMS patients (13.3%) stayed in disease active group (P = 0.014). (cellsurgicalnetwork.com)
  • Patients with limited disease (LD) concurrently received 50 Gy of irradiation with the last two cycles of PE. (the-medical-dictionary.com)
  • Two children are alive and well, with no evidence of disease 40 and 42 months after transplantation. (lu.se)
  • Patients then received interferon maintenance until disease recurrence. (cancertreatmenttoday.org)
  • Historically, patients with this debilitating disease have had limited treatment options, and disease-modifying agents were not available. (cancernetwork.com)
  • The principal contributing factor in the pathogenesis of the disease is insufficient blood supply to the femoral head resulting in necrosis of the femoral head. (ijpsonline.com)
  • Thus, through nuclear transfer and complementation, the normal human genome can be transferred into muscles of patients with genetic disorders to achieve phenotype repair or disease prevention. (jgc301.com)
  • Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. (tci-thaijo.org)
  • Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. (tci-thaijo.org)
  • pathology or laboratory medicine, is a medical speciality that is concerned with the diagnosis of disease based on the laboratory analysis of blood, urine, body fluid and tissues using the tools of chemistry, microbiology, hematology and molecular pathology. (kiranhospital.com)
  • Advanced gel technology is used for blood grouping and crossmatching .We have the facility to identify antibodies to minor red cell antigens(like kell, Kidd, C, E etc) which has the potential to cause haemolytic disease of the new born and haemolytic transfusion reaction. (kiranhospital.com)
  • Dr. Tallman focuses on the molecular genetics of APL, current curative treatment strategies and approaches for patients with relapsed and refractory disease. (ashpublications.org)
  • Noncancer disease group included cirrhotic patients ( n = 28) and spontaneous bacterial peritonitis (SBP) patients ( n = 11). (go.jp)
Significant6
  • Patients treated with isatuximab-RVd (six cycles) had lower numbers of collected stem cells compared to those receiving RVd (six cycles) induction (8.8 × 10 6 /kg bw versus 9.7 × 10 6 /kg bw, p = 0.801), without experiencing significant delays in LP or increased numbers of LP sessions in a multivariable logistic regression analysis. (biomedcentral.com)
  • There was no significant correlation between the PSA response and patients' age (p = 0.707). (shengsci.com)
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
  • However, a significant number of patients do not respond to growth factors and may continue to require frequent transfusions, which expose them to transfusion-related risks such as allo-sensitization and infections, without providing a definitive cure. (drugdiscoverynews.com)
  • The discovery of an activating point mutation in the Janus kinase 2 gene ( JAK2 V617F) in a significant portion of patients with MPNs led to improved understanding of the pathobiology of these disorders and prompted rapid development of JAK inhibitors. (cancernetwork.com)
  • While not a curative option, ruxolitinib offers great palliative potential and results in significant reduction in splenomegaly and improvement in constitutional symptoms in the majority of treated patients, thus improving their quality of life and performance status. (cancernetwork.com)